

## ASX RELEASE

### Volpara Quarterly Results and Investor Webinar Notification

Wellington, NZ, 19 October 2022: [Volpara Health Technologies](#) (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a global leader in software for the early detection and prevention of breast cancer, will be hosting an investor webinar on **Thursday 27<sup>th</sup> October 2022** at 9:00am AEDT (Sydney/Melbourne), 11:00am NZDT (Auckland/Wellington) to update shareholders on its quarterly financial results.

The call will be hosted by Teri Thomas, Managing Director, Craig Hadfield, Chief Financial Officer and Jill Spear, Executive Vice President of Sales and Marketing

#### Webinar details

**Date:** Thursday 27<sup>th</sup> October 2022  
**Time:** 9:00am AEDT (Sydney/Melbourne), 11:00am NZDT (Auckland/Wellington)  
**To register:** [https://us02web.zoom.us/webinar/register/WN\\_3rQOGpshT8y2Fsnjz5JOrA](https://us02web.zoom.us/webinar/register/WN_3rQOGpshT8y2Fsnjz5JOrA)  
**Dial in details:** Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to [hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### **Authorisation & Additional Information**

This announcement was authorised by the Group CEO of Volpara Health Technologies Limited.

**ENDS**

**For further information, please contact:**

#### **Corporate Enquiries**

Teri Thomas, CEO & MD  
Volpara Health Technologies  
[Teri.thomas@volparahealth.com](mailto:Teri.thomas@volparahealth.com)  
t: +64 4 499 6029

#### **Investor Relations**

Hannah Howlett  
WE Communications  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)  
t: +61 4 5064 8064

**About Volpara Health Technologies Limited (ASX: VHT)**

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A\$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand

For more information, visit [www.volparahealth.com](http://www.volparahealth.com).